- Home
- BDTX vs SJT Comparison
BDTX vs SJT Comparison
Compare BDTX & SJT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BDTX | SJT |
|---|---|---|
| Founded | 2014 | 1980 |
| Country | United States | United States |
| Employees | N/A | 495 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.9M | 139.8M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | BDTX | SJT |
|---|---|---|
| Price | $2.11 | $2.93 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $9.67 | N/A |
| AVG Volume (30 Days) | ★ 607.8K | 204.9K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 130.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.60 | $2.37 |
| 52 Week High | $4.94 | $6.61 |
Technical Indicators
Market Signals| Indicator | BDTX | SJT |
|---|---|---|
| Relative Strength Index (RSI) | 63.89 | 60.30 |
| Support Level | $2.13 | $2.85 |
| Resistance Level | $2.26 | $3.32 |
| Average True Range (ATR) | 0.10 | 0.14 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 86.92 | 75.34 |
Price Performance
Historical ComparisonAbout BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
About SJT San Juan Basin Royalty Trust
San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.